

Automation of Potency Assays: it's not plug-and-play, it's a journey CASSS May 6/7th 2019 Hermann Beck, F. Hoffmann-La Roche







To automate or not to automate,- why/when What is special for Automation of automation?

Bioassays

→ our considerations on relevant factors

Setting-up automation

Technical pitfalls *just one example*

Automation & GMP

Acceptance & Concerns



User/training concepts

Vision *new horizons for assay formats*




To automate or not to automate


- why/when automation?

"usual" expectations:










What is special for bioassay?




Many complex and repetitive pipetting (up to 430 pipetting steps/assay)



I had health problems/pain because of working on a laminar flow/pipetting

Yes (44%) No (56%) Sterile handling of cells and heterogenous workpackages






Result survey Bioassay labs Basel&Kaiseraugst, 34 responses


Roche

Efficiency gain: time saving





Balance benefit *from* – vs. effort *for* automation





Does automation pay off for us? A multitude of factors

No. of samples per time period

No. of different assays

No. of labs involved

Extend to which assays can be automated

••••



Does automation pays off only for high-throughput?

No. of samples per time period

No. of different assays

No. of labs involved

Extend to which assays can be automated

....

few different assays with high number of samples

VS.

many different assays with few samples

high throughput

high diversity

«rare assays»:

- → routine is lost
 - → require each time refamilarization
 - → increase of failure rate and time needed

Automation as tool to cope with high diversity



Does automation pay off for us? A multitude of factors

No. of samples per time period

No. of different assays

No. of labs involved




Extend to which assays can be automated

.

Transferability




Exchange of automated assays between labs



different, not harmonized automation solutions

→ no direct exchange of methods/ no smooth&easy transferability





Don't let us re-invent the wheel x-times, have x-times the effort, for ending up with x isolated solutions

→ starting point for the *Roche Global Bioassay Automation Team*



The Roche Global Bioassay Automation Team


















Balance benefit *from* – vs. effort *for* automation







HAMILTON-STAR Global Standard System defined

defined standard configuration

Pipetting channels, prepared for 96-head, gripper, no HEPA-filter, Balance for volume verification,

configurable deck-layout (carrier solution)

System specified in detail (part numbers) in a document



Storage and exchange of methodfiles via central server



Does automation pay off for us? A multitude of factors

No. of samples per time period

No. of different assays

No. of labs involved

Extend to which assays can be automated

.....



Bioassays can be automated to different extends

Sample preparation automation

= manual performed bioassay + automated pipetting

"Semi-" automated bioassay

- = manual cell suspension preparation
- + automated pipetting all other steps optional manual or automated

End-to-end automated bioassay

- = manual cell suspension preparation
- + *automated* pipetting/thermo incubation /plate washing/readout

Requires integration of peripherie (off-deck-handling)


Off-deck integration



E2E requires integration of additional devices

Sample dilutions and plating .

Pipetting device



- + minimized HOT
- + assays during nighttime
- higher effort for setup
- system is blocked for whole assay duration time






Keep flexibility

Case-by-case decision to do certain/different worksteps manualy or automated

depending on number and type of assays to be performed in a workpackage




Our approach



Central pipetting unit for sample-dilutions and —plating only

Module with off-deck of for E2E-automation

Both connected via robotic arm






Alternative/ additional strategy: the helping hand

Only dilution and plating,

but easy-to-use, small footprint, rel. cheap

→ Several per lab → no bottle-neck by systemblocking



Setup for GMP-purposes in progress





To automate or not to automate,- why when What is special for Automation of Bioassays

→ our considerations on relevant factors

Setting-up automation

Technical pitfalls *just one example*

Automation & GMP

Acceptance & Concerns



User/training concepts

Vision *new horizons for* assay formats


Setting-up an automated assay

Roche

- its not plug-and-play

Our very first automated ELISA

Comparison with manual performance



automated manually


first runs showed inconsistent results; partially high variances between automated and manual performed assays.

Technical pitfalls




Just one example

Spotting of position effects in automated assay for troubleshooting



Reason: minimal differences in absolute liquid levels led to partial aspiration of air



After adjustment of immersion depth, consistent results were obtained.

Fluorescein signal, deviation from average of wells with same theoretical concentration: blue > 5%; red > 10%


Setting-up an automated assay


Roche

- its not plug-and-play

After 19 revisions of the initial automated method:

manually and automated performed standard-ELISA showed equivalent results.






100% level

	manually	automated
N*	18	18
mean (PC)	94.5	94.8
CV [%]	5.8	3.5
variance	30.3	10.8

^{*} from 2 x 54 single plate results



→ analysis of samples can be performed both manually and automated



Setting-up an automated assay assay performance automated vs. manually

Target: «like-for-like», i.e. robot = another technician

 \rightarrow Idealy you can not see

in assay raw data, long-term trending data...

if assay was performed by

Technician A

Technician B

robot

→ To keep the flexibility to perform an assay manually or (partially) automated



The like-for-like concept and consequences for validation of automated assay

or

→ possible approaches for validation:

include robot as the additional technician in determination of

-Linearity/Accuracy

and/or

-Intermediate precision

and/or

-Robustness

«A robot is just a big pipette.

We do not validate our pipettes for every product. So why should we do it for a robot?»

the reward for hard labour: fast and easy set-up of new methods





optimized basis method used as framework for efficient programing of new methods

new method 1 Copy, change of steps and/or parameters

e.g. change of pipetted volumes, incubation times, insertion or cancelation of steps...etc.

new method 2





To automate or not to automate,- why when What is special for Automation of Bioassays

→ our considerations on relevant factors

Setting-up automation

Technical pitfalls *just one example*

Automation & GMP

Acceptance & Concerns



User/training concepts

Vision *new horizons for assay formats*

Automation & GMP



It may seem to be just a big pipette, but it's computerized!

- → CFR part11 compliance of software required
 - User management, account administration
 - Electronic records
 - Electronic signatures
 - It's complex & laborious, but doable Audit-trail (e.g. deletion of raw data)
 - Data integrity
 - Access control
 - Data security
 - Audit trail
 - Data review
 - Change control
 - Virus protection/security concept
 - Incident management
 - Separation of development and GMP on the same system



User/training concepts

Not everyone needs to be an expert

Our approach

Superusers: high level of expertize (can program, attended vendors trainings).
 At least 2.

System qualification & maintenance; develop methods; troubleshooting; connected to global network; train the users... → link between lab/users to global network and vendor....


• **Users:** trained by superusers; contact superuser for troubleshooting or any other questions. Potentialy all technicians performing assay.

Run automated GMP-methods.



Automation has a dimension beyond businesscases and technical items

When implementing automation you may face a brought spectrum of motivation, acceptance, reservations and concerns



Finally, it's the ususal evolution of change: polarization / scepticism \rightarrow familarization \rightarrow implicitness

How could we work without it?


...I would never go back

Roche

Vision

new horizons for assay formats

Automation should allow e.g. to use more complex assay formats



→ Expected increase in quality and efficiency, but exceeding of what can manually be accomplished, i.e. can only be done by a robot

Summary



- If automation is of benefit *below the bottom-line for your organization* depends on a multitude of factors,- many of them are difficult to be calculated just as a business case, many are work-task and organization specific
- Match/adapt extend of automation with your specific needs.
 - A modular setup for a stepwise implementation and usage of automation provides flexibility
- when implementing automation be prepared for
 - many technical obstacles and that a steep learning curve is needed
 - that psychological barriers of staff may be an issue
- Automation & GMP: possible, but complex,- a particular challenge
- Automation opens new horizons regarding assay formats







the Roche Global Bioassay Automation Team

Jason Mango

Kathleen Sampson

Adelheid Rohde

Patrick Heim

Jay Leone

Brian Murphy

Terence Ng

Jan Bohuslav

Charlotte Giesen

Cheryl Headlee

Klaus Leonhard

Maggie Lee

Sebastian Scholz

Zachary Wyatt

Till Koenig

Julia Tolle

Louise Pritchett

Kiernan Ammerman

Kathrin Ostermaier

Silvia Loeblein

Christel Richter



Doing now what patients need next